At the news
? NEUTRALIMPACT 5/10 8-K filed Aug 4, 2026 at 07:36 ET
ImmunityBio reported record Q2 2026 net product revenue of $50.7M, up 92% YoY and 15% sequentially, marking the eighth consecutive quarter of growth. The FDA accepted the sBLA for ANKTIVA in BCG-unresponsive NMIBC with a PDUFA date of Jan 6, 2027.
- Q2 2026 net product revenue of $50.7M, up 92% YoY and 15% sequentially from Q1 2026.
- First-half 2026 net product revenue of $94.8M, up 121% YoY.
- FDA accepted sBLA for ANKTIVA in BCG-unresponsive NMIBC with papillary-only disease; PDUFA date Jan 6, 2027.
- GAAP net loss attributable to common stockholders was $230.4M in Q2 2026 vs $92.6M in Q2 2025.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access